Donor-derived cytotoxic T-lymphocytes directed against myeloma-associated antigens such as Wilms tumor 1 (WT1) or other cancer testis antigens (76, 77) may enable a GVM effect without GVHD. Here, WT1 is linked to plasma cell myeloma.